cardiovascular disease

Overview

Cardiovascular disease (CVD) is an umbrella term encompassing a broad spectrum of disorders affecting the heart and blood vessels, including coronary artery disease (CAD), heart failure, stroke, peripheral artery disease, and arrhythmias such as atrial fibrillation/flutter. As the leading cause of morbidity and mortality worldwide, CVD arises from a complex and multifactorial interplay of genetic predisposition, metabolic dysfunction, chronic inflammation, oxidative stress, and environmental exposures. Pathophysiologically, the disease is driven by endothelial dysfunction, atherosclerotic plaque formation, thrombosis, and mitochondrial impairment, with upstream contributors including dyslipidemia (particularly elevated LDL cholesterol and lipoprotein(a)), insulin resistance, hypertension, and systemic inflammation mediated through pathways such as the PI3K/AKT/mTOR axis, NF-κB signaling, and Wnt/β-catenin signaling. These shared mechanisms mean CVD rarely occurs in isolation—it is deeply interconnected with type 2 diabetes, chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), and obesity, a convergence now formalized under the Cardiovascular-Kidney-Metabolic (CKM) syndrome framework.

Beyond classical risk factors, emerging research has identified roles for epigenetic regulation, including blood DNA methylation, gut microbiota composition, mitochondrial biogenesis, and autophagy dysregulation in CVD pathogenesis. The involvement of Sirtuin 1 (SIRT1), PRKAA1, prostaglandin E2, Gasdermin D (GSDMD)-mediated pyroptosis, and proinflammatory cytokines such as IL-17A illustrates the molecular complexity underlying cardiovascular pathology. Gene Editing Technologies including CRISPR-Cas12a, alongside multi-omics approaches integrating genomics, proteomics, and metabolomics, are increasingly being deployed to disentangle this complexity and identify novel therapeutic targets. CVD thus represents one of the most intensively studied domains in modern biomedical science, with translational research spanning from basic molecular biology to population-scale epidemiology.

Recent Publications Summary

Recent publications on cardiovascular disease have focused heavily on risk stratification, biomarker discovery, and the influence of comorbid conditions and environmental exposures. Several studies examined cardiovascular disease in the context of Cardiometabolic comorbidity, including type 2 diabetes, type 1 diabetes, and CKM syndrome. In type 2 diabetes, substance use disorders were evaluated for their association with cardiovascular disease and all-cause mortality 42297744Jun, while in type 1 diabetes, chronic low-grade inflammation and metabolic syndrome were assessed for their impact on coronary artery disease risk, with hs-CRP used as the inflammatory marker 42054898Apr. In early CKM syndrome stages 0–3, the SPISE index and ensemble machine learning were explored to refine cardiovascular risk stratification 42101474May, and another prospective cohort study is assessing the individual and combined effects of ambient air pollution mixtures on cardiovascular disease risk in this population 42361027Jun.

Multiple publications investigated biomarkers and physiological measures linked to cardiovascular disease or coronary artery disease. Plasma ASGR1 was reported as a potential diagnostic biomarker for coronary artery disease and a predictor of adverse outcomes in hypertensive patients, with higher levels associated with more severe coronary lesions and adverse clinical phenotypes 42048115Apr. Blood pressure was studied alongside proteomic vascular ageing, with the aim of determining whether proteomic vascular ageing mediates the relationship between high blood pressure and incident cardiovascular events 41346045Dec. Sclerostin inhibition was also examined using instrumental genetic variants to estimate whether sustained therapeutic inhibition is associated with altered cardiovascular disease risk, including atrial fibrillation 42218280May. In addition, a study of humidity metrics in older adults found associations between several humidity indicators and heart disease risk, with mixing ratio and vapor pressure deficit emerging as key predictors 42201577May.

Other studies addressed broader risk prediction and disease progression. Free-text clinical records were mapped to structured features to support heart disease classification using LightGBM, combining unstructured narratives and structured datasets to automatically extract risk factors and predict heart disease presence or absence 42507733Jul. A modular deep learning architecture was developed for interpretable disease prediction across tabular clinical and biometric datasets, including the UCI Heart Disease dataset, to improve generalizable and explainable prediction workflows 42102106May. Phenotypic age acceleration was also studied in relation to asthma progression, subsequent cardiovascular disease, and death, with genetic risk and lifestyle considered as modifiers 42184546May. In pediatric hematopoietic stem cell transplantation survivors, a protocol was outlined to estimate the prevalence of metabolic syndrome, vascular damage, and accelerated aging, reflecting concern for later cardiovascular disease burden in this population 42302269Jun.

Additional work highlighted cardiovascular disease in relation to hospitalization outcomes and preventive interventions. In adults hospitalized for diabetic foot ulcer, readmitted patients had a higher prevalence of cardiovascular disease, and cardiovascular comorbidities were among the factors associated with 30-day readmission 42053128Apr. A pilot randomized clinical trial tested gamification to improve medication adherence among patients at risk of cardiovascular disease with prior nonadherence, reflecting interest in low-cost behavioral interventions to reduce cardiovascular risk 41802527Mar.

What Changes, What Holds

1. Cardiometabolic context now drives finer cardiovascular risk stratification
NEW DIRECTION Work in diabetes and CKM syndrome does not overturn the baseline mechanisms of endothelial dysfunction, dyslipidemia, and inflammation; it extends them into more practical risk layering. The new studies suggest that substance use, low-grade inflammation, metabolic syndrome, and even ambient pollution mixtures may materially alter risk estimates in people already carrying cardiometabolic disease, especially in early CKM stages. That makes cardiovascular disease look less like a single downstream outcome and more like a risk state whose expression depends on comorbidity and exposure context 42297744Jun42054898Apr.

2. New biomarkers and vascular-ageing measures may refine prediction, but clinical utility remains unsettled
REINFORCES Plasma ASGR1 and proteomic vascular ageing fit the baseline’s emphasis on biomarker discovery and multi-omics, adding candidate tools rather than changing the disease model. The main implication is translational: cardiovascular disease may be more accurately risk-stratified by combining circulating markers with physiologic ageing signatures and blood pressure, but these findings still need validation before they can guide routine care. The sclerostin analysis also keeps the question open rather than settled, because it tests whether long-term inhibition alters risk instead of assuming neutrality 42048115Apr41346045Dec.

3. Prediction is shifting toward interpretable machine learning and multimodal clinical data
METHOD These studies change how cardiovascular disease is studied and classified, not what is known about its biology. Free-text extraction, structured feature mapping, and modular deep learning expand the toolkit for identifying risk factors and predicting disease presence from routine records and tabular datasets. That is useful for phenotyping and deployment, but it does not challenge the baseline account of pathogenesis. The practical consequence is better model transparency and generalizability, with cardiovascular disease serving as a test bed for clinical AI rather than a newly redefined entity 42507733Jul42102106May.

4. Cardiovascular burden is emerging as a downstream consequence in nontraditional clinical settings
NEW DIRECTION The baseline does not discuss cardiovascular disease as a complication signal in hospitalized diabetic foot ulcer patients, so this work adds a new clinical context rather than revising established mechanisms. It suggests that cardiovascular comorbidity meaningfully shapes readmission risk and may need to be considered in discharge planning and follow-up for high-risk inpatients. The gamification trial similarly points to prevention through adherence support, but that is an intervention strategy, not a change in disease biology. Together they broaden the settings in which cardiovascular disease matters clinically 42053128Apr41802527Mar.

Overview update candidates: comorbidity-linked risk stratification in diabetes and CKM syndrome; biomarker-based risk refinement; cardiovascular comorbidity in readmission risk; adherence-focused prevention.